April 30, 2014 / 11:17 AM / 4 years ago

BRIEF-Sales of Genmab's Arzerra fell to 15.6 mln GBP in Q1

COPENHAGEN, April 30 (Reuters) - Danish biotech company Genmab said on Wednesday: * Worldwide net sales of cancer drug Arzerra (ofatumumab) in the first quarter of 2014 totaled 15.6 million pounds ($26.28 million) down from 20.5 million punds in the same quarter last year. * Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately 28 million Danish crowns ($5.18 million)

Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below